tetano
Editor, Senior Moderator
Vaccine
. 2024 Jul 8:S0264-410X(24)00785-0.
doi: 10.1016/j.vaccine.2024.07.024. Online ahead of print. Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in pregnancy: A prospective cohort study
I Korchinski[SUP] 1 [/SUP], C Marquez[SUP] 2 [/SUP], E McClymont[SUP] 3 [/SUP], G Av-Gay[SUP] 4 [/SUP], J Andrade[SUP] 1 [/SUP], C Elwood[SUP] 5 [/SUP], A Jassem[SUP] 6 [/SUP], M Krajden[SUP] 6 [/SUP], M Morshed[SUP] 6 [/SUP], M Sadarangani[SUP] 7 [/SUP], G Tanunliong[SUP] 8 [/SUP], I Sekirov[SUP] 6 [/SUP], D Money[SUP] 9 [/SUP]
Affiliations
Objectives: To measure and evaluate the impact of receiving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in pregnancy on immunoglobulin G (IgG) and immunoglobulin A (IgA) titres in maternal and infant samples.
Design: Prospective cohort study.
Setting: Tertiary obstetric centre.
Population or sample: 52 pregnant women who received one or more SARS-CoV-2 vaccine doses during pregnancy and their neonates.
Methods: IgG and IgA concentrations against SARS-CoV-2 antigens were measured from samples collected at delivery and 4-6 weeks postpartum and compared using Spearman correlations.
Main outcome measures: Maternal and infant IgG and IgA titres in response to vaccination and infection in pregnancy.
Results: In maternal serum collected at delivery, participants without evidence of prior infection who received 3 + doses of a SARS-CoV-2 vaccine had higher Anti-Spike (S) IgG geometric mean concentrations (log[SUB]10[/SUB] AU/mL)(GMC) than those who received 2 doses (3 + Doses = 5.00, 2 Doses = 4.60, p = 0.08). The differences in IgG Anti-S GMC were statistically significant in cord serum, and in postpartum samples of maternal serum, infant serum and breast milk (Cord GMCs: 3 + Doses = 5.32, 2 Doses = 4.98, p < 0.05; Postpartum maternal serum GMCs: 3 + Doses = 5.25, 2 Doses = 4.57, p < 0.001; Postpartum infant serum GMCs: 3 + Doses = 5.10, 2 Doses = 4.72, p = 0.03; Postpartum breast milk GMCs: 3 + Doses = 2.61, 2 Doses = 1.94, p < 0.0001). Among participants with 3 + Doses, those with evidence of SARS-CoV-2 infection had statistically significant higher anti-S IgG GMCs than those without prior infection (Maternal serum at delivery: SARS-CoV-2+=5.65, SARS-CoV-2-=5.00, p = 0.004; Cord: SARS-CoV-2+=5.68, SARS-CoV-2-=5.32, p = 0.02; Postpartum maternal serum: SARS-CoV-2+=5.66, SARS-CoV-2-=5.25, p < 0.001; postpartum infant serum: SARS-CoV-2+=5.50, SARS-CoV-2-=5.10, p = 0.003; Postpartum breast milk: SARS-COV-2+=3.25, SARS-COV-2-=2.61, p = 0.009). Significant positive correlations were found for anti-S IgG titres between paired maternal and infant samples at delivery and postpartum (Delivery: R = 0.91, p < 0.001; postpartum: R = 0.86, p < 0.001).
Conclusions: Receipt of a SARS-CoV-2 vaccine and SARS-CoV-2 infection elicit strong IgG and IgA antibody responses in pregnant women with evidence of transplacental transfer to the fetus.
Keywords: Antibody; Breast milk; Immunoglobulins; Pregnancy; SARS-CoV-2; Vaccination.
. 2024 Jul 8:S0264-410X(24)00785-0.
doi: 10.1016/j.vaccine.2024.07.024. Online ahead of print. Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in pregnancy: A prospective cohort study
I Korchinski[SUP] 1 [/SUP], C Marquez[SUP] 2 [/SUP], E McClymont[SUP] 3 [/SUP], G Av-Gay[SUP] 4 [/SUP], J Andrade[SUP] 1 [/SUP], C Elwood[SUP] 5 [/SUP], A Jassem[SUP] 6 [/SUP], M Krajden[SUP] 6 [/SUP], M Morshed[SUP] 6 [/SUP], M Sadarangani[SUP] 7 [/SUP], G Tanunliong[SUP] 8 [/SUP], I Sekirov[SUP] 6 [/SUP], D Money[SUP] 9 [/SUP]
Affiliations
- PMID: 38981741
- DOI: 10.1016/j.vaccine.2024.07.024
Objectives: To measure and evaluate the impact of receiving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in pregnancy on immunoglobulin G (IgG) and immunoglobulin A (IgA) titres in maternal and infant samples.
Design: Prospective cohort study.
Setting: Tertiary obstetric centre.
Population or sample: 52 pregnant women who received one or more SARS-CoV-2 vaccine doses during pregnancy and their neonates.
Methods: IgG and IgA concentrations against SARS-CoV-2 antigens were measured from samples collected at delivery and 4-6 weeks postpartum and compared using Spearman correlations.
Main outcome measures: Maternal and infant IgG and IgA titres in response to vaccination and infection in pregnancy.
Results: In maternal serum collected at delivery, participants without evidence of prior infection who received 3 + doses of a SARS-CoV-2 vaccine had higher Anti-Spike (S) IgG geometric mean concentrations (log[SUB]10[/SUB] AU/mL)(GMC) than those who received 2 doses (3 + Doses = 5.00, 2 Doses = 4.60, p = 0.08). The differences in IgG Anti-S GMC were statistically significant in cord serum, and in postpartum samples of maternal serum, infant serum and breast milk (Cord GMCs: 3 + Doses = 5.32, 2 Doses = 4.98, p < 0.05; Postpartum maternal serum GMCs: 3 + Doses = 5.25, 2 Doses = 4.57, p < 0.001; Postpartum infant serum GMCs: 3 + Doses = 5.10, 2 Doses = 4.72, p = 0.03; Postpartum breast milk GMCs: 3 + Doses = 2.61, 2 Doses = 1.94, p < 0.0001). Among participants with 3 + Doses, those with evidence of SARS-CoV-2 infection had statistically significant higher anti-S IgG GMCs than those without prior infection (Maternal serum at delivery: SARS-CoV-2+=5.65, SARS-CoV-2-=5.00, p = 0.004; Cord: SARS-CoV-2+=5.68, SARS-CoV-2-=5.32, p = 0.02; Postpartum maternal serum: SARS-CoV-2+=5.66, SARS-CoV-2-=5.25, p < 0.001; postpartum infant serum: SARS-CoV-2+=5.50, SARS-CoV-2-=5.10, p = 0.003; Postpartum breast milk: SARS-COV-2+=3.25, SARS-COV-2-=2.61, p = 0.009). Significant positive correlations were found for anti-S IgG titres between paired maternal and infant samples at delivery and postpartum (Delivery: R = 0.91, p < 0.001; postpartum: R = 0.86, p < 0.001).
Conclusions: Receipt of a SARS-CoV-2 vaccine and SARS-CoV-2 infection elicit strong IgG and IgA antibody responses in pregnant women with evidence of transplacental transfer to the fetus.
Keywords: Antibody; Breast milk; Immunoglobulins; Pregnancy; SARS-CoV-2; Vaccination.